Elevated CA19-9 is Associated with Increased Mortality in A Prospective Cohort of Hepatocellular Carcinoma Patients

Clinical and Translational Gastroenterology

Volumn 6, Issue , 2015, Pages

  Hsu, Christine C ^a   Goyal, Abhishek ^a   Iuga, Alina ^b   Krishnamoorthy, Saravanan ^a   Lee, Valerie ^a   Verna, Elizabeth C ^a   Wang, Shuang ^a   Chen, Fei Na ^c   Rodriguez, Rosa ^a   Emond, Jean ^a   Berk, Paul ^a   Lefkowitch, Jay ^b   Dove, Lorna ^a   Brown, Robert S ^a   Siegel, Abby B ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Department of Medicine   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN;

ADULT; ARTICLE; BARCELONA CLINIC LIVER CANCER STAGE; BILE DUCT; BLOOD LEVEL; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CHILD PUGH SCORE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER NODULE; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MODEL FOR END STAGE LIVER DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEM CELL;

EID: 84923170148     PISSN: 2155384X     EISSN: None     Source Type: Journal    
DOI: 10.1038/ctg.2014.22     Document Type: Article

References (40)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
2. Bova V, Miraglia R, Maruzzelli L et al. Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies. Cardiovasc Intervent Radiol 2013; 36: 433-439.
3. Shao YY, Lin ZZ, Hsu C et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116: 4590-4596.
4. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134: 1342-1351.
5. Schwartz M, Dvorchik I, Roayaie S et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008; 49: 581-588.
6. Iizuka N, Oka M, Yamada-Okabe H et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-929.
7. Llovet JM. Clinical and molecular classification of hepatocellular carcinoma. Liver Transpl 2007; 13: S13-S16.
8. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 2012; 3: 105-119.
9. Marrelli D, Caruso S, Pedrazzani C et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009; 198: 333-339.
10. Basso D, Meggiato T, Fabris C et al. Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases. Eur J Clin Invest 1992; 22: 800-804.
11. Liu ZH, Chen Z, Ma LL et al. Factors influencing the prognosis of patients with intrahepatic cholangiocarcinoma. Acta Gastroenterol Belg 2012; 75: 215-218.
12. Kim KH, Lee SG, Park EH et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol 2009; 16: 623-629.
13. Wan P, Zhang J, Long X et al. Serum levels of preoperative alpha-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation. Eur J Gastroenterol Hepatol 2014; 26: 553-561.
14. Chen YL, Chen CH, Hu RH et al. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection. Scientific WorldJournal 2013; 2013: 380797.
15. Bader TR, Beavers KL, Semelka RC. MR imaging features of primary sclerosing cholangitis: patterns of cirrhosis in relationship to clinical severity of disease. Radiology 2003; 226: 675-685.
16. Cooperberg PL, Li D, Wong P et al. Accuracy of common hapatic duct size in the evaluation of extrahepatic biliary obstruction. Radiology 1980; 135: 141-144.
17. Hakansson K, Ekberg O, Hakansson HO et al. MR characteristics of acute cholangitis. Acta Radiol 2002; 43:175-179.
18. Collazos J, Genolla J, Ruibal A. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study. Clin Chim Acta 1992; 210: 145-151.
19. Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria-chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009; 23: 49-60.
20. Hakeem AR, Young RS, Marangoni G et al. Systematic review: the prognostic role of alphafetoprotein following liver transplant for hepatocellular carcinoma. Aliment Pharmacol Ther 2012; 35:987-999.
21. Tyson GL, Duan Z, Kramer JR et al. Level of alpha-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 989-994.
22. Libbrecht L, Desmet V, Van Damme B et al. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000; 33: 76-84.
23. Mishra L, Banker T, Murray J et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009; 49: 318-329.
24. Lai Q, Avolio AW, Manzia TM et al. Role of alpha-fetoprotein in selection of patients with hepatocellular carcinoma waiting for liver transplantation: must we reconsider it? Int J Biol Markers 2011; 26: 153-159.
25. Hsu SX, Siegel AB, Berk PD. A 70-year-old woman with 10 years of markedly elevated alpha-fetoprotein measurements. Semin Liver Dis 2010; 30: 99-106.
26. Shim JH, Yoon DL, Han S et al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol 2012; 19: 3687-3696.
27. Chantajitr S, Wilasrusmee C, Lertsitichai P et al. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg 2006; 13: 537-542.
28. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
29. Ziol M, Nault JC, Aout M et al. Intermediate hepatobiliary cells predict an increased risk of hepatocarcinogenesis in patients with hepatitis C virus-related cirrhosis. Gastroenterology 2010; 139: 335-343.
30. Cai X, Zhai J, Kaplan DE et al. Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology 2012; 56: 1804-1816.
31. Lee JS, Heo J, Libbrecht L et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-416.
32. Holczbauer A, Factor VM, Andersen JB et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 2013; 145: 221-231.
33. Taguchi J, Nakashima O, Tanaka M et al. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 1996; 11: 758-764.
34. Maeda T, Adachi E, Kajiyama K et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol 1995; 26: 956-964.
35. Sapisochin G, de Lope CR, Gastaca M et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study. Ann Surg 2014; 259: 944-952.
36. Yin X, Zhang BH, Qiu SJ et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 2012; 19: 2869-2876.
37. Liver Cancer Study Group of Japan Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211: 277-287.
38. Toyoda H, Kumada T, Kiriyama S et al. Impact of tumor factors on the prognosis of patients with advanced cirrhosis (Child-Pugh class C) and hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20: 963-965.
39. Nishikawa H, Kita R, Kimura T et al. Clinical efficacy of non-transplant therapies in patients with hepatocellular carcinoma with Child-Pugh C liver cirrhosis. Anticancer Res 2014; 34: 3039-3044.
40. Kawai S, Suzuki K, Nishio K et al. Smoking and serum CA19-9 levels according to Lewis and secretor genotypes. Int J Cancer 2008; 123: 2880-2884.